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Precis: Is salvage surgery a one size fits all approach, and more importantly, in the era of 
improved systemic therapy what are the criteria based on which salvage surgery for SCCHN 
should be the uncontested modality of choice 
 
Treatment for recurrent squamous cell carcinoma of the head and neck (SCCHN) remains a 
challenge and the disease carries significant burden for patients and families. While the overall 
survival of patients with locally advanced SCCHN has improved with the addition of platinum 
based chemotherapy to definitive radiation [1], significant numbers of patients continue to fail [2, 
3].  It is estimated that 30-40 % of patients treated with definitive therapy will recur, the majority 
loco-regionally [4, 5]. Patients with recurrent disease are faced with few curative options and are 
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desperate for modalities that prolong life expectancy while preserving key functions and quality 
of life.  
While salvage surgery (SS) has been advocated as the modality of choice to achieve these 
goals, its indication remains poorly defined, with a significant risk of complications of up to 67% 
[2, 6, 7]. It is clear that while patients may benefit from SS, the outcome of a number who are 
offered this modality remains poor [7]. Even though age and performance status are important 
predictors of patient outcome[8, 9], clear guidelines determining eligibility are lacking [7].  SS 
has not been compared directly to re-irradiation given the obvious challenges to implement such 
a trial, and the difficulty interpreting non-randomized data given the lack of uniformity and 
inherent selection biases.  
In  the locally recurrent and metastatic setting, we witnessed improvements with the addition of 
cetuximab to the platinum backbone leading to the adoption of the EXTREME regimen as a new 
standard of care a decade or so ago [10]; yet despite these advances, practices and 
recommendations for SS continued to be untested.. It is noteworthy in that respect, that patients 
are enrolled on systemic therapy trials often based on exclusion of SS, thereby introducing 
inherent bias rendering retrospective comparisons impossible to perform.  
Recently, as immunotherapy has evolved in a relatively short time into a new standard for 
patients with advanced incurable heavily pre-treated SCCHN with two immune check–point 
inhibitors (ICPI) approved in 2016 [11, 12],  we believe  it is time to look at our long held 
practices in a new light [13]. Historically while induction chemotherapy has failed to produce 
significant improvement in patient survival, pre-operative single doses of ICPI have produced 
impressive responses with little toxicity in different tumor types including SCCHN [14]. 
Chemoresponders consistently show improved survival and increased responses to subsequent 
radiation. Of significance as well, is that bio-selection with induction chemotherapy has achieved 
impressive cure rates in laryngeal cancers[15]. While the picture remains unclear as far as the 
best way to use ICPI in the definitive setting, there is every reason to believe the standard of 
care for locally advanced SCCHN will soon change. As single agent ICPI can result in long term 
progression free and overall survival for some heavily pretreated patients, it is legitimate to ask 
whether combination ICPI approaches may result in this much desired outcome for at least a 
percentage of patients currently offered SS who continue to fare poorly despite aggressive 
surgery. A plausible innovative strategy here would be induction immunotherapy for bio 
selection and subsequent decision regarding the need for SS versus continued systemic 
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therapy. It is worth noting that current trials are already exploring the impact of induction 
immunotherapy in the locally advanced settings and can inform similar designs of future SS 
trials. Of importance as well is that HPV status appears to influence the rate of pathologic 
remissions noted with SS, pointing to the fact that future trials or guidelines will need to account 
for HPV [16]. In addition, the effect center volume and expertise has on outcome of patients 
treated on such trials need to be accounted for [17].  
The difficult questions that need to persist are: 1) is salvage surgery a one size fits all approach, 
and more importantly, 2) in the era of immune-oncology, what are the criteria based on which 
SS should be the uncontested modality of choice? Getting closer to clarity will require taking 
courageous steps. The first step would be to consider clinical trial designs targeting patients 
where clear indications for SS have not been established. Getting there will require a meeting of 
the leading experts in the various therapeutic disciplines. Lessons from the not too distant past 
are worth remembering; those include but are not limited to the lack of improvement in larynx 
cancer mortality despite the increase in the non-surgical management of this disease; Needless 
to say that factors such as side effects expected from immunotherapy, the rare but concerning 
phenomenon of hyper-progression, the cost of ICPI, as well as surgical and center expertise, 
need to be taken into consideration when evaluating ICPI in the context of SS and must be 
factored in the outcome measure designs of such studies.  
 
This editorial was written by members of the International Head and Neck Scientific Group 
www.IHNSG.com 
 
 
1. Pignon JP, et al., Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update 
on 93 randomised trials and 17,346 patients. Radiother Oncol., 2009. Jul;92(1):4-14. doi: 
10.1016/j.radonc.2009.04.014. Epub 2009 May 14. 
2. Tan HK, et al., Salvage surgery after concomitant chemoradiation in head and neck squamous 
cell carcinomas – stratification for postsalvage survival. Radiother Oncol., 2010. Jul;92(1):4-14. 
doi: 10.1016/j.radonc.2009.04.014. Epub 2009 May 14. 
Au
th
or
 M
an
us
cr
ip
t
This article is protected by copyright. All rights reserved 
3. Galloway TJ, et al., Prognostic Value of p16 Status on the Development of a Complete Response 
in Involved Oropharynx Cancer Neck Nodes After Cisplatin-Based Chemoradiation: A Secondary 
Analysis of NRG Oncology RTOG 0129. Int J Radiat Oncol Biol Phys, 2016. Oct 1;96(2):362-371. . 
4. Ang, K.K., et al., Human papillomavirus and survival of patients with oropharyngeal cancer. N 
Engl J Med, 2010. 363(1): p. 24-35. 
5. Ang, M.K., et al., High XRCC1 protein expression is associated with poorer survival in patients 
with head and neck squamous cell carcinoma. Clin Cancer Res, 2011. 17(20): p. 6542-52. 
6. Esteller E, et al., Salvage surgery after locoregional failure in head and neck carcinoma patients 
treated with chemoradiotherapy Eur Arch Otorhinolaryngol 2011. 268(2):295-301. 
7. Hamoir M, et al., Salvage surgery in recurrent  head and neck squamous cell carcinoma: 
Oncologic outcome and predictors of disease free survival. Oral Oncol 2017. Apr 67: 1-9. 
8. Ho AS, et al., Decision making in the management of recurrent head and neck cancer. Head 
Neck, 2014. 36(1):144-51. 
9. Kim J, et al., Selection of ideal candidates for surgical salvage of head and neck squamous cell 
carcinoma: effect of the Charlson-Age Comorbidity Index and oncologic characteristics on 1-year 
survival and hospital course. JAMA Otolaryngol Head Neck Surg, 2015. 141(12):1059-65. 
10. Vermorken JB, et al., Platinum-based chemotherapy plus cetuximab in head and neck cancer. N 
Engl J Med, 2008. Sep 11;359(11):1116-27. 
11. Ferris RL, et al., Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N Engl 
J Med 2016. Nov 10;375(19):1856-1867. . 
12. Bauml J, et al., Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: 
Results From a Single-Arm, Phase II Study. J Clin Oncol, 2017. May 10;35(14):1542-1549. 
13. Harrington KJ, et al., Nivolumab versus standard, single-agent therapy of investigator's choice in 
recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-
related quality-of-life results from a randomised, phase 3 trial. Lancet Oncology, 2017. 
Aug;18(8):1104-1115. . 
14. Uppaluri R, et al., Neoadjuvant pembrolizumab in surgically resectable, locally advanced HPV 
negative head and neck squamous cell carcinoma (HNSCC). J Clin Oncol, 2017 35, no. 15_suppl 
(May 20 2017) 6012-6012. 
15. Wolf GT, et al., Survival Rates Using Individualized Bioselection Treatment Methods in Patients 
With Advanced Laryngeal Cancer. JAMA Otolaryngol Head Neck Surg, 2017. Apr 1;143(4):355-
366. 
Au
th
or
 M
an
us
cr
ip
t
This article is protected by copyright. All rights reserved 
16. Galloway TJ, et al., Prognostic Value of p16 Status on the Development of a Complete Response 
in Involved Oropharynx Cancer Neck Nodes After Cisplatin-Based Chemoradiation: A Secondary 
Analysis of NRG Oncology RTOG 0129. Int J Radiat Oncol Biol Phys. 2016, 2016. Oct 1;96(2):362-
371. 
17. Wuthrick EJ, et al., Institutional clinical trial accrual volume and survival of patients with head 
and neck cancer. J Clin Oncol, 2015. Jan 10;33(2):156-64. 
 
Au
th
or
 M
an
us
cr
ip
t
